Syneos Health trades as part of the healthcare sector and trades as part of the medical diagnostics and research industry. The company CEO is Alistair Macdonald. Syneos Health Inc is a Contract Research Organization providing clinical development services for biopharmaceutical and medical device industries. It operates in North America, Europe, Middle East and Africa, Asia-Pacific and Latin America.
Previous Intraday Trading Performance:
The SYNH stock showed a previous change of 0.79% with an open at 47.21 and a close of 47.12. It reached an intraday high of 47.67 and a low of 46.33.
The stock has a market cap of $4.9b with 103.8m shares outstanding, of which the float is 102.8m shares. Trading volume reached 486,503 shares compared to its average volume of 641,316 shares. Based on the current average volume and close price, the trading liquidity is good.
Historical Trading Performance:
Over the last five trading days, Syneos Health shares returned 4.53% and in the past 30 trading days it returned 0.40%. Over three months, it changed 10.98%. In one year it has changed 9.07% and within that year its 52-week high was 56.34 and its 52-week low was 36.27. SYNH stock is 29.93% above its 52 Week Low.
Our calculations show a 200 day moving average of 47.32 and a 50 day moving average of 46.00. Currently SYNH stock is trading -0.43% below its 200 day moving average and may be a good opportunity to buy, but should check other indicators to confirm a buy signal.
The last annual fiscal EPS for the company was reported at 0.23 that ended on 31st of December 2018, which according to the previous close, that is a PE of 204.87. Based on 6 analyst estimates, the consensus EPS for the next quarter is 0.51. The TTM EPS is 2.62, which comes to a TTM PE of 17.98.
Below was the last reported quarterly diluted earnings per share:
|1st||Qtr of 2019||(Reported on 05/09/2019):||-0.29|
|4th||Qtr of 2018||(Reported on 03/18/2019):||0.44|
|3rd||Qtr of 2018||-0.10|
|2nd||Qtr of 2018||0.13|
|1st||Qtr of 2018||-0.24|
Base on our calculations, the intrinsic value per share is 81.30, which means it is possibly undervalued and has a margin of safety of 42.04%.
Indicators to Watch:
The current calculated beta is 1.46.
SeekingAlpha: Greif, Inc. 2019 Q2 – Results – Earnings Call Slides
Based on last reported financials, the company’s return on equity is 0.69%, return on assets is 0.27%, profit margin is 0.40%, price-to-sales is 1.09 and price-to-book is 1.71.
All scores are out of six:
3 :Valuation Score
0 :Past Performance Score
2 :Financial Strength Score
3 :Future Growth Score
0 :Dividend Score
2 :Overall Score